Zencurix Partners with Chinese Female Cancer Diagnosis Company 'Yusun' for Breast Cancer Prognosis Prediction Service

[Asia Economy Reporter Hyunseok Yoo] Zencurix announced on the 1st that it has signed a memorandum of understanding (MOU) with Beijing Yusun Medical Testing Laboratory Co., Ltd. (hereinafter Yusun), a Chinese female cancer specialized diagnostic company, for the service of Jinswell BCT, a breast cancer prognosis prediction test, in China.

Yusun, headquartered in Beijing, China, is a female cancer specialized diagnostic company established with investment from BGI (Beijing Genomics Institute), the top gene analysis company in China. It operates a diagnostic center capable of providing breast cancer prognosis diagnostic services locally in China. Equipped with a breast cancer specialized sales organization covering all of China, Yusun was finally selected as a partner to jointly promote Zencurix’s Jinswell BCT business in China.

After launching Jinswell BCT in the domestic market, Zencurix signed an MOU last year with the Clinical Center of Zhejiang University Hospital in China for joint clinical research, mutual support for regulatory approval, and academic networks in China. It is also promoting clinical research cooperation with Peking University Hospital (Beijing), Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing), and Fudan University Hospital (Shanghai). Through this strategic alliance with Yusun, it is expected that actual service sales in China will be possible starting in the second half of the year.

Zencurix’s Jinswell BCT is a test for early breast cancer patients that assesses the risk of recurrence or distant metastasis within 10 years, identifying patient groups who can expect high survival rates without undergoing chemotherapy. In China, although the annual number of new breast cancer patients is estimated to exceed 400,000, the breast cancer prognosis prediction test market is still in the introduction stage, making it a market expected to grow significantly in the future. Zencurix plans to quickly capture the Chinese market before Western breast cancer tests are introduced by emphasizing that Jinswell BCT is more suitable for Asian breast cancer patients.

Yusun possesses gene extraction equipment and PCR equipment for the Jinswell BCT test at its own diagnostic center. With years of molecular diagnostic technology and experience, as well as a sales network targeting breast cancer KOLs, it is expected to provide breast cancer prognosis diagnostic test services stably within China.

Hyunwook Park, Vice President of Zencurix, said, “Since the end of last year, when the entire top management of Yusun visited our company and proposed cooperation plans, we have been steadily discussing practical cooperation methods. A clear consensus has been formed between the two companies regarding the growth potential of the Chinese breast cancer prognosis diagnostic test market, and based on this, starting from Beijing in the second half of the year, Jinswell BCT testing will be made available at major hospitals throughout China by next year.”